Key Highlights

  • Kestra Medical Technologies reported first quarter fiscal 2027 Revenue of 31 million dollars, up 60 percent year over year, exceeding both company and analyst expectations.
  • Gross Margin expanded to 56.5 percent, marking the eleventh consecutive quarter of sequential gross margin improvement.
  • The company raised its long-term gross margin target to the mid-70 percent range, up from its prior 70 percent goal, and increased full fiscal year revenue guidance to 141 million dollars.
  • Kestra ended the quarter with 245 million dollars in cash and investments and secured a new 200 million dollar non-dilutive term Loan Facility in July.

Strong start to fiscal 2027 with continued margin expansion

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a Kirkland, Washington-based commercial-stage wearable medical device company focused on cardiac monitoring and therapeutic intervention, reported first quarter fiscal 2027 revenue of 31 million dollars, an increase of 60 percent compared with the prior year period. Revenue growth was driven by continued expansion of the wearable cardioverter defibrillator market, competitive share gains against the category's incumbent, and a rising mix of in-network patients supported by ongoing revenue cycle management improvements.

Gross margin reached 56.5 percent, an increase of more than 10 percentage points year over year and 175 basis points sequentially, marking the company's eleventh consecutive quarter of sequential gross margin expansion. Based on this trajectory, management raised its long-term gross margin target to the mid-70 percent range within the next few years, up from its previously communicated target of 70 percent.

Expanding Market Share and investing in AI-driven productivity

The company's commercial growth strategy centers on deepening penetration within existing high-volume territories by splitting them and adding clinical account specialists, a model management said compounds growth by increasing the number of prescribers reached within a market. Management noted that despite substantial clinical evidence supporting wearable cardioverter defibrillator therapy, approximately six out of seven patients indicated for the therapy in 2025 remained unprotected, underscoring the scale of the category's remaining growth opportunity, which management estimates grew approximately 14 percent on a dollar basis over the twelve months ended July 2026.

Kestra is also prioritizing three areas of AI and automation investment: patient support and adherence, revenue access and collections, and commercial Demand acceleration aimed at increasing fittings per sales representative without a proportional increase in headcount. Management described this Investment as building toward meaningful Operating Leverage in future years, while acknowledging that the associated cost curve improvements are expected to become more visible starting in fiscal 2028 and 2029 rather than the current fiscal year.

Balancing an aggressive growth trajectory against cash burn

The company's raised fiscal 2027 revenue guidance of 141 million dollars, representing 48 percent growth, is supported by improving in-network payer coverage, which has risen from approximately 70 percent of fittings at the time of the company's IPO to the low 80s currently, along with continued expansion of its sales territory coverage. If second-half acceleration materializes as management projects, driven by newly hired sales representatives reaching full productivity, the company could see a meaningful step-up in quarterly revenue relative to the first quarter's run rate.

Balanced against this growth trajectory, the company reported a GAAP net loss of 44.1 million dollars for the quarter and cash used in Operating Activities of 32.3 million dollars, with management indicating that quarterly cash burn is expected to decline sequentially through the fiscal year, consistent with the pattern observed in fiscal 2026. The company's continued investment in late-stage research and development, including an undisclosed new product initiative expected to be detailed in future quarters, adds a degree of near-term spending that will require sustained revenue growth to offset.

A growth story anchored in expanding, underpenetrated demand

Kestra Medical Technologies' first quarter results reflect continued execution against a large and underpenetrated wearable cardioverter defibrillator market, with revenue growth, gross margin expansion, and payer coverage improvements all moving in a consistent direction. The company's raised long-term margin targets and revenue guidance suggest management sees a durable multi-year growth runway ahead. Whether the anticipated second-half acceleration from newly ramped sales representatives materializes as projected will be an important indicator for the remainder of fiscal 2027.